

Decrease in the resources allocated to the liquidity contract entrusted to Invest Securities

Paris, March 5, 2024 – 5:45 pm CET – Ikonisys SA (ISIN code: FR00140048X2 / Ticker: ALIKO) announces that it has decreased by €32,000 on March 4, 2024, the resources allocated to its liquidity agreement with INVEST SECURITIES, pursuant to the decision of the French Financial Market Authority (the “*Autorité des marchés financiers*” or “AMF”) n°2021-01 on June 22nd, 2021 (the “AMF decision”).

As of March 4, 2024, after market close and decrease in the amount of cash allocated to the liquidity contract of €32,000, the available resources are as follows:

- 44,840 shares
- 15,899.67 € in cash

As a reminder, as of the half year statement on 31/12/2023, the following assets appeared on the liquidity account:

- 46,657 shares
- 45,119.60 € in cash

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20[®] and Ikoniscope20max[®] platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.ikonisys-finance.com

Contacts

Ikonisys

Alessandro Mauri
CFO
investors@ikonisys.com

NewCap

Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94

NewCap

Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98